A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53
Open Access
- 15 September 2021
- journal article
- letter
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (9) , e537
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82072826, 81872088, 81972867, 81773257)
- Natural Science Foundation of Guangdong Province (2018B030306023)
This publication has 7 references indexed in Scilit:
- CasX enzymes comprise a distinct family of RNA-guided genome editorsNature, 2019
- Engineering cell signaling using tunable CRISPR–Cpf1-based transcription factorsNature Communications, 2017
- Multiplex gene editing by CRISPR–Cpf1 using a single crRNA arrayNature Biotechnology, 2016
- CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineeringNature Biotechnology, 2013
- CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in EukaryotesCell, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- MYC on the Path to CancerCell, 2012